The therapeutic strategy targeting CAFs-mediated FGF5/FGFR2 axis in TME might augment DDP sensitivity and reduce the effective dose of DDP, thus decreasing the side effects of DDP in NPC. The gene discussed is FGF5; the disease is nasopharyngeal carcinoma.